trajectori year clear meet dilig
data week reinforc convict sector
growth highlight convict strengthen
debat chang sentiment shift
us learn confer call estimate today dial
us confer id
earli macro scorecard yet definit maintain attract view
devic sector outlook given better fundament vs
broader healthcar along histor defens natur sector
maintain growth-ori bia ytd scorecard
admittedli earli yet definit neither growth vs valu smid vs
larg cap seen rel perform evid
continu winner intuit irhythm
modest revers last year laggard baxter hill-rom
suggest perform larg idiosyncrat versu themat
devic modestli under-perform healthcar result
coverag under-perform ytd given ep
estim move lower rel fundament continu look
stronger devic
feel recent rate chang
upgrad baxter overweight view compani lower
growth profil discount path acceler
commentari meet support view fluid
busi stabil contract go well manag
commit disciplin capit deploy remain confid
path growth
downgrad globu equal-weight view headwind
robot earn make out-performance challeng
view still hold pre-announc result guidanc point
stronger share gain base spinal implant busi offset gap
saw estim consensu
downgrad underweight base less attract
growth profil versu peer cynosur recoveri look labor
underappreci competit risk surgic pre-announce
result organ growth vs mse driven acceler
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
breast post organ growth strongest quarter year
thesi remain intact cynosur weak persist report y/i
declin rais question whether growth attain
surgic perform rel line expect
continu believ competit pressur like increas
debat move
case durabl took hit indic cvg
would lower lvad risk elimin upsid ep growth
could pressur bp result higher tax rate fx
potenti come lrp target updat model
price target move reflect multipl
ep discount versu in-lin multipl prior given question
around return profil
risk pharmaci drive price headwind dexcom
pre-announce top-line sale mse guid sale
growth incorpor least pt price headwind
seen clear underli volum growth outpac price
continu expect outperform top end guidanc
pharmaci risk mitig earlier libr icgm launch
pre-announc solid result shift strategi hf
alon new platform launch late offer multipl
treatment modal confirm clinic path db
encourag chang commerci strategi address issu
origin laid downgrad last year model lose us
share year see risk multipl emerg competit
entrant saluda stimwav biotronik etc compani execut
new commerci strategi mitig headwind
given growth trend debat head
center margin expans potenti new ceo chri barri
like drive addit invest notabl plan
robot pre-announc sale shift debat
highlight execut strateg risk come ceo
transit bring question whether growth trajectori
sentiment shift
sustain growth abbott key debat confid
deliv top-line growth continu increas believ
assumpt key driver upsid libr mitraclip
underappreci next gen libr could launch via icgm
pathway coapt driven mitraclip inflect necessari
deliv abbott outlook tax headwind off-set
debt restructur core margin expans remain comfort
ep growth
med-tech typic see pt tailwind emerg market
em hill-rom howev discuss manag
suggest cadenc drive long-term double-digit growth em
busi degre materi could add anoth pt hill-
rom growth profil supplement pipelin centrella
connex retinavu drive growth mid-singl digit
si-bon pre-announce result slightli
expect us revenu growth offset
intern weak compani acceler sale forc hire
faster pace anticip specialist hire took place
januari fast start updat payor coverag decis
addit inform around deform opportun aao later
quarter like catalyst stock
irhythm under-perform coverag point
highlight least expens stock rel growth
remain enthusiast out-performance manag guid
rep hire suggest signific commerci expans
seen continu confid full commerci
launch like begin expect bigger
financi driver
insid topic interest detail gilti paclitaxel risk
compani updat increment data point week pre-
topic interest
paclitaxel risk focu paclitaxel risk drug elut devic key topic
boston becton compani remain defens paclitaxel-
mortal relationship impli meta-analysi compani independ
evalu patient level data conclud relationship view remain
meta-analysi hypothesi gener earli definit conclus
kol dilig call suggest limit impact devic util unclear
analysi meaning impact commun base physician util look
forward updat linc next week viva symposium februari assess
paclitaxel risk individu compani exposur
gilti disclosur spark concern whether new tax
regul could lead broader uptick tax rate multi-national corpor
updat guidanc see much setback incorpor
expect addit bp upward pressur tax rate
driven gilti global intang low-tax incom base eros
anti-abus tax anti-hybrid rule increment neg howev
dilig suggest major compani coverag previous
incorpor item prior commentari guidanc outlin specif
tax commentari select compani larg cap coverag
morgan stanley research streetaccount thomson reuter note mid-point use varianc rang provid
continu expect guidanc remain comfort near high end
rang
libr come possibl via icgm pathway mitraclip focal
point collect drive bp growth manag includ
coapt driven mitraclip acceler could key driver upsid
tax like bp y/i headwind off-set
debt restructur margin expans see gilti remain
comfort ep growth
pre-announce sale street rais guidanc
beat y/i growth seem conserv new fy
guidanc impli bp momentum deceler
us sale beat mse repres modest deceler
ex us sale repres materi momentum acceler driven
faster expect pace japan launch
approv launch us calendar year end encourag
driver maintain growth
manag pleas progress on-q recoveri believ
mainli issu compani seen progress
anticip progress well avano focus convert
surgeon account direct custom leiter help
pharmacist hospit fill pump differ way
avano finish year two post- ip separ quarter
manag believ reason baselin margin
compani see cost save offset reinvest
manag express confid target present may
analyst day growth earn cash flow compani fallen
short growth plan share analyst day
issu seen temporari structur
innov pipelin paid signific dividend yet
manag confid come year manag note
enrol clinic trail on-demand pd solut gener system
exampl highlight number pipelin driver januari upgrad
baxter continu patient disciplin potenti acquisit
manag expect execut deal come year
prior year absenc compani continu activ share
buyback long believ share trade discount
lvp perform like pressur tougher comp
baxter releas constraint previous place
like easier comp lvp
bd reiter guidanc provid ep call remain confid
deal model year guidanc includ underli ep guidanc
deal model
relat headwind tailwind resin price come
less headwind fx gotten wors headwind net
meta-studi dcb suggest paclitaxel correl mortal see
bd remain confid safeti efficaci lutonix per intern data
share data come month compani dcb outlook remain unchang
manag discuss certain headwind fx order time would
lead revenu growth toward lower end guidanc rang
suggest ep would discuss dynam
outlook alreadi lower ep estim
boston pre-announc organ growth beat mse bp
repres bp acceler broadli boston seven key segment
acceler deceler one stabl see januari note
path toward acceler clear remain confid boston
abil deliv cc growth close high end rang
tax guidanc effect rate begin encourag peer
face y/i headwind see gilti remain comfort
driven sbc benefit
risk pharmaci drive price headwind dexcom
pre-announce top-line sale mse guid sale growth
incorpor least pt price headwind
seen clear underli volum growth outpac price
continu expect outperform top end guidanc
growth expans new geographi ex us driver upsid japan approv
reimburs come later year like driver
possibl headlin risk identifi stori sooner expect
libr approv us via icgm pathway
guidanc decemb analyst day unchang focu continu
low risk data march pascal launch europ see
long term tavr growth hing upon indic expans low risk
asymptomat earli tavr geograph expans expect
market grow unchang
mitral tricuspid market grow unchang
analyst day manag expect launch pascal europ
globu beat sale expect driven base busi
specif globu grew us spinal implant busi quarter
organ reflect bp comp-adjust acceler
globu revenu guidanc expect model
like driven better expect base busi
comfort growth us base busi believ globu guidanc
pleas see januari note detail
manag remain confid abil deliv lrp doubl ebit
quadrupl
haemonet convert collect center nexsi believ
underli plasma market grow compani increas
plasma collect dispos capac meet grow plasma demand
manag market deal hospit divis like focu
tuck-in
manag reiter guidanc remain confid hill-rom
achiev lrp goal core growth organ pipelin
emerg market drive growth bp weight averag
med-tech typic see pt tailwind emerg market em
hill-rom howev discuss manag suggest
cadenc drive long-term double-digit growth em busi degre
materi could add anoth pt hill-rom growth profil
supplement pipelin centrella connex retinavu drive growth
mid-singl digit
hospit capital-expenditure environ remain healthi notic chang
custom capit purchas capit deploy
pre-announce sale consensu
midpoint guidanc
beat larg driven breast focal
faxitron beat estim translat organ growth
strongest quarter year impli pt comp-adjust acceler
cynosur weak persist report revenu y/i declin
miss estim rais concern cynosur abil
return growth
surgic rel line howev believ competit like becom
increas area focu come month
pleas see downgrad underweight januari note detail
cfo transit wayd mcmillan unexpect wayd
mitg vice-president financ effect covidien cfo strong hire
see
transit pharmaci focu dash roll-out
catalyst transit may lead quarterli volatil expect y/i
improv growth back half weight see outlook
horizon ap progress pivot expect timelin unchang
launch
integra pre-announce result point sale upper end guidanc
beat consensu expect bp organ sale expect grow
slightli greater organ reflect bp comp-adjust
manag expect organ sale growth headwind fx
tsa payment estim bring report sale growth
expect lowest growth quarter acceler throughout year
integr continu product launch ramp
integra expect publish studi amnioexcel help
integra announc licens develop agreement cfo consortium
focus orthopedist short stem stemless shoulder system
pleas see januari note detail
preliminari result reinforc underli growth trend intuit remain
strong fifth consecut quarter procedur
momentum acceler gross system placement growth greater
procedur growth guidanc modestli better anticip
expect bullish sign view given intuit recent histori
attempt conserv expect
china intuit announc xi approv begin direct oper
fosun jv intuit sell system china
follow recent quota announc system
expect sale start although major system sale may occur
later two year period
follow reimburs approv japan april notabl
step system placement system last two quarter
signific acceler procedur growth
pleas see januari note detail
manag guid rep hire respit rep hire
increas rep product revenue rep continu increas
time remain comfort rep add said outlook
zio roll-out bigger focu expect manag
commentari broader roll-out increas throughout year said
financi driver
 remain confid babi powder safe scienc support
discuss previous see talc reaction flaw scienc
saw sell-off follow reuter articl overdon
manag discuss headwinds/tailwind tailwind includ
expand indic imbruvica darzalex stelara launch/uptak
erleada tremfya improv execut md over-the-counter beauti
babi relaunch consum headwind includ patent
expirations/competit zytiga remicad procrit tracleer concerta
comfort report revenu growth rate
next year margin think pharma headwind greater
model pharma growth still market consum growth
md growth underli margin drop-through headwind discuss
like sever expect lower margin
estim model ep ep growth
case durabl took hit indic cvg would
lower lvad risk elimin upsid ep growth could pressur
bp result higher tax rate fx potenti come
lrp target pleas much setback detail
adjust model rais tax rate beyond
bp increas midpoint manag commentari
ep estim move reduct price target move
reflect multipl ep discount versu
in-lin multipl prior given question ep durabl pleas see
risk reward detail bull base bear case scenario
pre-announc result vs mse
midpoint pleas see solid quarter focu detail
compani announc new platform launch late offer hf
tradit stimul burst confirm clinic path db
encourag chang commerci strategi address issu
origin laid downgrad last year
model lose us share year see risk multipl
emerg competit entrant saluda stimwav biotronik etc
compani execut new commerci strategi mitig
headwind
estim grew organ reflect pt
comp-adjust deceler vs level disappoint result driven
lower volum specif surgeon delay capit sale
commentari point stabl spine market prior commentari
compani earn call point moder healthier spine market
margin opportun still key valu driver commentari
suggest could longer time frame compani invest drive growth
new ceo chri barri pleasantli surpris robot strategi
although limit detail share robot becom key part full
procedur solut spine catch globu robot
may necessari protect grow share long-term nass robot
pleas see januari note detail
pre-announce revenu y/i growth slightli
ahead estim consensu
us revenu y/i beat estim off-set
intern weak like driven continu spend constraint
rep hire acceler faster pace previous suggest
specialist hire made vs prior estim januari
fast start believ hire made date
compani discuss plan begin train sale forc deform
come week expect detail opportun come aao
march see initi coverag addit detail deform
pleas see januari note detail
pre-announc result includ new order total largest order
quarter histori addit manag complet backlog
review suggest fewer system expect remov
backlog go forward remov prior quarter
us sale team fulli built work
intern europ japan direct footprint distribut
standpoint manag expect team impact
manag expect cash util decreas
cash cash burn
pleas see januari note detail
continu believ guid organ growth
consist lrp target manag reiter sever pocket
conservat built includ dtd convers opportun ii pipelin
potenti bp iii neotract expect pt organ growth
neotract rep hire cadenc expect continu rep annual
invest like ramp behind dtc market roll-out urolift
launch
materi updat pipelin discuss although expect
updat follow earn call manta pma process panel vs
panel ii repla bla submiss iii pipelin financi contribut
light recent commentari tax regul comfort
model tax rate vs prior result increment
headwind ep howev slightli off-set increment fx
tailwind compar previou estim ep estim
consensu midpoint ep guidanc expect
commentari point organ growth growth improv
impact new launch build suppli improv fx expect
bp headwind sale growth focus bill day
neutral year fewer day off-set day
zimmer biomet open dialog fda concern remedi effort
north campu compani work execut
prioriti around portfolio optim remain bring weight averag
market growth rate wamgr higher zimmer biomet capac
smaller tuck-in deal current compani abl open
playbook debt paydown continu
manag expect approv rosa spine knee full
launch expect
better execut lead multipl expans
better execut lead multipl expans
deriv base case scenario price target reflect
ep discount larg cap peer
total return profil achiev
consist organ sale growth
least bp ebit margin expans
return back
like lower
see organ revenu guidanc
achiev given comp product
drive bp annual margin expans
bull case ep
bull case ep
reset expect execut organ growth trend
sustain new launch off-set competit headwind ep growth
doubl digit aggress capit deploy drive upsid
top-line growth estim bp
top-line growth contribut ep
margin estim bp ebit
margin drive ep
base ep
base ep
total return profil long-term profil mid-singl digit
organ growth bp margin expans high-singl digit ep
growth total return profil howev question durabl
achiev profil lead discount versu peer
bear ep
bear ep
end market slow take top-line organ growth fall
manag mid-singl digit guidanc underli leverag harder
come given lower growth earn growth reach mid upper
new product launch uptak high
intelli neurosurgeri neurovascular
ration margin
risk achiev price
db tavr dcb linq
slowdown acceler emerg
less repurchas activ materi
price target base multipl base case
ep line high growth larg cap peer see
multipl reflect abbott better peer top bottom line growth nutrit
recov china imf headwind fade aler stabil gradual return market
growth new product libr confirm mri launch mitraclip
inflect sustain organ growth profil medium term management execut
deal synergi margin grow per year support ep
base case valuat use price-to-earnings valuat larg cap peer
believ justifi given better top bottom line growth line high
growth peer
valu driver includ continu oper margin expans core abbott
combin cost synergi execut st jude aler organ growth
acceler driven devic product launch diabet ep structur heart
risk price target includ emerg market macro slowdown fx headwind
strengthen us dollar failur deliv synergi target and/or growth
acceler aler failur libr mitraclip drive top-line growth
price target reflect multipl base case
sale multipl high growth devic peer support dcf
valuat assum wacc termin growth increas visibl stemi
drive increment valu discount wacc assum sale grow
driven continu impella penetr protect pci shock impella
growth remain medium term market expans initi take time
develop growth continu inflect stemi repres meaning
expans opportun posit feasibl data rapidli scale busi
reach ebit margin multipl remain high growth
peer lack competit under-penetrated market support impella
revenu growth compound-annual-growth-rate
risk pt includ failur demonstr sustain impella growth
call growth sustain question ii emerg competit ahead
expect market growth present attract opportun new entrant
pressur share price iii reimburs risk annual drg reimburs
variabl
price target base ebitda discount back use
ebitda normal cost transform plan follow ip unit
sale multipl discount peer given lower organ growth partial off-set
signific margin expans opportun transform proce estim
high avano grow top-line low mid singl digit give headwind
margin start lower consensu appreci path toward margin improv
move forward plan
risk price target includ top-line revenu grow upper singl digit signific
near-term recoveri on-q pain pump avano execut larg accret
price target base dcf use wacc termin
growth rate peak margin impli sale discount back
year take share grow market axon launch late rapidli
reach upper-teen market share within year differenti product featur
drive share captur innov acceler snm market growth mid-teen
risk price target includ axon r-snm product fda approv current
physician relationship could sticki imagin make difficult gain
share next-gener competit respons eventu slow share gain
market appetit high-growth pre-profit compani could deterior
impact multipl regardless fundament
price target reflect multipl base case
ebitda in-line peer given lower wamgr off-set margin expans
opportun assum organ growth margin reach
risk includ medic deliveri nutrit recov expect ii
potenti activ below- wacc return iii inabl gener oper
leverag iv baxter struggl grow wamgr
price target base multipl base case
ebitda reflect premium peer organ growth improv becom
evid new product ramp cost program gain traction bard
synergi integr track bd/bard deal model drive mid-teen
risk price target includ integr fall behind schedul promis
synergi fail materi ii macro trend get wors competit pressur em
mount iii new product launch fail live expect
price target base multipl base case
ep assum trade larg cap peer justifi superior emerg
growth margin expans opportun leverag profil line high
growth peer ew sustain execut support
acceler high singl digit large-cap growth stori recent build pipelin
program drive sale compound-annual-growth-rate oper margin remain
track bp annual improv next sever year drive mid-teen
risk price target includ unfavor legal develop increas competit
core de market competit product launch failur execut
plan pipelin program integr
price target reflect ev sale multipl base
case sale line high growth smid cap devic compani
support dcf valuat assum wacc termin growth rate
risk price target includ guardian libr competit greater
expect limit new patient start materi increas attrit ii dexcom
traction medicar limit coverag guardian libr come sooner
expect iii libr forc signific price pressur limit path
profit delay failur pipelin catalyst
price target deriv dcf valuat assum wacc
termin growth model project tavr market growth billion
drive ebit margin incorpor valu reflect mitral
risk price target includ acceler competit
us near term robust commerci traction boston abbott/st jude
long term ii potenti pipelin develop failur mitral space
market opportun could larger aortic least sever year away iii
reimburs structur us europ could put downward pressur price
time
price target deriv discount cash flow valuat impli
core busi ebitda valu globu robot program
trauma launch
risk price target includ increas turnov among sale forc
lower iv robot uptak limit
price target adr assum class share trade one
year forward earn grifol histor turn premium european
pharma adr trade discount class share consist
averag valuat spread past sever year
risk price target includ narrow valuat spread adr vs class
share ii addit accret could drive upsid estim iii stabil
competit situat us ivig could support favor price trend
price target reflect ev/ebitda estim premium
upsid risk price target includ higher price benefit nexsi ii
identif addit cost opportun iii capit deploy downsid
risk includ nexsi disappoint ii cost save fail materi iii blood
bank slow materi iv teg disappoint
price target reflect ev/ebitda multipl discount smid
cap med-tech given leverag lower growth pipelin product move hill-rom
structur organ growth rate time mix cost initi drive
margin line lrp improv stabil growth visibl
margin improv drive multipl higher
risk price target includ pipelin traction slow fail materi
upcom product ii margin leverag prove difficult iii
materi shift capital-expenditure environ
price target base multipl base case
ebitda discount larg cap devic peer market satur
increas regul limit cynosur growth segment grow expect
growth rate increas competit surgic lead novasur declin breast
grow lsd-msd new product launch recent drive growth
diagnost price risk manag off-set panther placement
util deliv organ sale growth high singl digit ep growth
risk price target includ deploy capit enter faster growth end
market drive ep growth greater expect share buyback
synergi ii cynosur recov faster anticip abl achiev doubl
digit growth profil iii novasur manag competit threat
price target reflect ev sale multipl base
case discount high growth smid cap peer ex us growth
improv meaning ypsome gross up near term disrupt fade
us growth remain stabl driven medicar shift
pharmaci mdi pediatr posit insul omnipod ap competitor
risk remain path sale pipelin product sustain growth
gm clear like floor dash roll horizon ap launch
base case reflect ev sale multipl
discount high growth smid cap peer
downsid risk includ insulet lose market share ap competitor ii limit
convers anima patient iii ypsome disrupt greater expect iv
dash horizon ap timelin slip path profit becom less clear upsid
risk includ minim disrupt ypsome transit ii disclosur
